Live Chat

Los Contratos por diferencia («CFD») son instrumentos complejos que comportan un riesgo elevado de pérdidas rápidas debido al apalancamiento. El 76,3% de las cuentas de inversores particulares pierde dinero al operar CFD con este proveedor. Debe considerar si comprende el funcionamiento de los CFD y si puede permitirse asumir un riesgo elevado de perder su dinero.

Close

BioNTech gráfico en tiempo real

Perspectivas

Weekly Search
Weekly
Daily
date Cerrar change Cambio del % Apertura Alto Bajo

Markets.com news

bitcoin rising
Alec Malloy 2024 Aug 19, 16:05

Test News Spanish Article Only

BoE Acciones
French election results to drive European markets
markets.com Support Team 2024 Jul 04, 21:00

Adelanto semanal: Los resultados de las elecciones francesas clave para los mercados europeos

Forex Índices
Macron calls snap election, riles markets
markets.com Support Team 2024 Jun 29, 21:00

Adelanto semanal: ¿Francia desencadenará la próxima crisis del euro?

CPI
Businessman pointing hologram online banking icon.
markets.com Support Team 2024 Jun 20, 16:00

Adelanto semanal: Muchos datos e información sobre la inflación

Forex Índices

Información

Spread

0.9949

Spread (%)

0.8754 %

Apalancamiento

1:5

Interés a un día (Compra)

-0.0597 %

Interés a un día (Venta)

-0.0292 %

Divisa

USD

Horarios de los mercados

Markets closed

Martes

14:31 - 20:59

Lunes

14:31-20:59

Miércoles

14:31-20:59

Jueves

14:31-20:59

Viernes

14:31-20:59

Estado de resultados

Apertura

---

Cierre anterior

---

Máximo/mínimo de 52 semanas

--- – ---

Capitalización de mercado

27212888064

Acciones en circulación

239740000

Fecha de ganancias (próxima)

0000-00-00

instr__dividend_date

2022-06-17

instr__ex_dividend_date

2022-06-02

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

GPA

-2.01

Acciones en circulación

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

Conoce más sobre este instrumento

Activo
Vender
Comprar
Cambio del %
Instrumentos relacionados
Trustpilot
Live Chat